Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
Aravive, Inc. (Nasdaq: ARAV) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Gail McIntyre and CMO Reshma Rangwala will engage in a virtual fireside chat, available for viewing on September 13 at 7:00 AM ET. Aravive will also hold one-on-one meetings during the event. The company focuses on developing innovative therapeutics for life-threatening diseases, notably its lead therapeutic, AVB-500, which targets the GAS6-AXL pathway and has received Fast Track Designation for platinum-resistant recurrent ovarian cancer.
- None.
- None.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The Company’s presentation will be available for viewing on September 13, 2021 at 7:00 AM ET. Aravive will also participate in one-on-one meetings at the conference.
This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of www.aravive.com. An archived replay of the webcast will be available for 90 days following the webcast.
About Aravive
Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anticancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.
Contact:
Joseph T. Schepers
VP, Investor Relations, Aravive, Inc.
jschepers@aravive.com
(770) 558-5517
FAQ
When is Aravive participating in the H.C. Wainwright 23rd Annual Global Investment Conference?
Who will represent Aravive at the investment conference?
What time will Aravive's presentation be available?
What is AVB-500 and its significance in cancer treatment?
What designation has AVB-500 received from the FDA?
